Literature DB >> 2567672

A comparison of the extent and duration of hypokalaemia following three nebulized beta 2-adrenoceptor agonists.

C D Burgess1, A Flatt, R Siebers, J Crane, R Beasley, G Purdie.   

Abstract

The hypokalaemic effects of equal doses (5 mg) of fenoterol, salbutamol, terbutaline and an equal volume of saline administered by nebulization were compared in eight healthy subjects. Plasma potassium was measured at 15-min intervals for 60 min and at 90 min, 2, 4 and 6 h following administration. Fenoterol, salbutamol and terbutaline all significantly decreased plasma potassium when compared to saline; however, the magnitude and duration of this effect differed between the active agents. Both fenoterol and terbutaline significantly reduced plasma potassium for 4 h whereas salbutamol was only different from 30 to 120 min. The maximum decrease occurred with fenoterol (-0.78 mmol/l), followed by terbutaline (-0.70 mmol/l) and salbutamol (-0.33 mmol/l). Both terbutaline and fenoterol had a significantly greater effect compared with salbutamol. When administered by nebulization fenoterol and terbutaline are likely to have a greater hypokalaemic effect than salbutamol and this effect is likely to be more long lasting.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2567672     DOI: 10.1007/BF00558306

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Patients at risk for dying of asthma: New Zealand experience.

Authors:  M R Sears; H H Rea
Journal:  J Allergy Clin Immunol       Date:  1987-09       Impact factor: 10.793

Review 2.  The role of adrenal medullary catecholamines in potassium homoeostasis.

Authors:  A D Struthers; J L Reid
Journal:  Clin Sci (Lond)       Date:  1984-04       Impact factor: 6.124

3.  Cardiovascular and biochemical responses to nebulised salbutamol in normal subjects.

Authors:  S R Smith; C Ryder; M J Kendall; R Holder
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

4.  Ventricular arrhythmias and hypokalaemia.

Authors:  P Curry; D Fitchett; W Stubbs; D Krikler
Journal:  Lancet       Date:  1976-07-31       Impact factor: 79.321

Review 5.  Fenoterol: a review of its pharmacological properties and therapeutic efficacy in asthma.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-01       Impact factor: 9.546

6.  Prior thiazide diuretic treatment increases adrenaline-induced hypokalaemia.

Authors:  A D Struthers; R Whitesmith; J L Reid
Journal:  Lancet       Date:  1983-06-18       Impact factor: 79.321

7.  Cross-over study of the efficacy of four beta 2-sympathomimetic bronchodilator aerosols.

Authors:  B W Madsen; M K Tandon; J W Paterson
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

8.  Metabolic responses to beta 2 stimulants.

Authors:  S R Smith; M J Kendall
Journal:  J R Coll Physicians Lond       Date:  1984-07
  8 in total
  5 in total

1.  Effect of beta 2-adrenoceptor agonists on plasma potassium and cardiopulmonary responses on exercise in patients with chronic obstructive pulmonary disease.

Authors:  C T Yang; H C Lin; M C Lin; C H Wang; C H Lee; H P Kuo
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

2.  Diuretic-related hypokalaemia: the role of diuretics, potassium supplements, glucocorticoids and beta 2-adrenoceptor agonists. Results from the comprehensive hospital drug monitoring programme, berne (CHDM).

Authors:  P Widmer; R Maibach; U P Künzi; R Capaul; U Mueller; R Galeazzi; R Hoigné
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

3.  The cardiovascular effects of beta adrenergic agonist drugs administered by nebulisation.

Authors:  A Flatt; J Crane; G Purdie; T Kwong; R Beasley; C Burgess
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

4.  Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarction.

Authors:  S Suissa; T Assimes; P Ernst
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

5.  Rejection of hemolyzed samples can jeopardize patient safety.

Authors:  Lorenzo Barbato; Marise Danielle Campelo; Sara Pigozzo; Nicola Realdon; Anna Gandini; Roberto Barbazza; Mayara Ladeira Coêlho; Chiara Bovo; Paola Marini; Gabriel Lima-Oliveira
Journal:  EJIFCC       Date:  2020-03-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.